Harmonising clinical trials within the Gynecologic Cancer InterGroup: consensus and unmet needs from the Fifth Ovarian Cancer Consensus Conference
Harmonising clinical trials within the Gynecologic Cancer InterGroup: consensus and unmet needs from the Fifth Ovarian Cancer Consensus Conference
复制标题
DOI：
10.1093/annonc/mdx449
复制
发表时间：
2017-11-01
影响因子：
50.5
通讯作者：
Ochiai, K.
中科院分区：
文献类型：
--
作者：
Bookman, M. A.;Okamoto, A.;Ochiai, K.
第五届卵巢癌共识会议（GCIG Fifth Ovarian Cancer Consensus Conference，OCCC）于2015年11月7日至9日在日本东京举行。它就4个主题领域的15个重要问题提供了国际共识，这些问题是根据建立“设计更好临床试验的国际共识”的使命声明产生的。在第五次OCCC会议期间，先前确定并遵循了获得共识的方法。GCIG的所有29个临床试验组都参与了项目的开发和审议。在专题小组和全体论坛上讨论了协商一致声明草案。最后声明随后提交给所有29个成员组进行表决，并记录协商一致的程度。15项声明中有11项获得了完全共识，28/29组同意3项声明，27/29组同意1项声明。试验组对这些陈述的高接受率反映了这样一个事实，即我们有共同的问题，并认识到重要的未满足的需求，这些需求将指导未来的卵巢癌研究。
The Gynecologic Cancer InterGroup (GCIG) Fifth Ovarian Cancer Consensus Conference (OCCC) was held in Tokyo, Japan from 7 to 9 November 2015. It provided international consensus on 15 important questions in 4 topic areas, which were generated in accordance with the mission statement to establish 'International Consensus for Designing Better Clinical Trials'. The methodology for obtaining consensus was previously established and followed during the Fifth OCCC. All 29 clinical trial groups of GCIG participated in program development and deliberations. Draft consensus statements were discussed in topic groups as well as in a plenary forum. The final statements were then presented to all 29 member groups for voting and documentation of the level of consensus. Full consensus was obtained for 11 of the 15 statements with 28/29 groups agreeing to 3 statements, and 27/29 groups agreeing to 1 statement. The high acceptance rate of the statements among trial groups reflects the fact that we share common questions, and recognise important unmet needs that will guide future research in ovarian cancer.